English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Medication-related osteonecrosis of the jaws (MRONJ) has multiple exogenous and endogenous risk factors. The risk of MRONJ associated with anti-resorptive drugs (Bisphosphonates  and Denosumab) was reviewed in oncological and osteoporotic patients referred to the Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome (Italy), since January 2019 to January 2021. The incidence of MRONJ was analyzed according to local (dental extraction), systemic risk factors (diabetes, steroid, ecc), medication type, and drug treatment duration. The intake of Zolendronate was strongly associated with osteonecrosis of the jaws in oncological patients and the risk of MRONJ was higher in patients with metastases regardless of the type of anti-resorptive therapy. The use of Bisphosphonates  and Denosumab was very common in the treatment of osteoporosis, up to 42.4% of the patients, and the incidence of MRONJ was higher than previously reported. It was possible to prevent the occurrence of MRONJ after oral surgery due to medical prophylaxis, non-traumatic surgical procedures, and photobiomodulation therapy (PBMT).

qeios

A SINGLE REFERENCE CENTER, 2 YEARS RETROSPECTIVE STUDY ON THE RISK FACTORS ASSOCIATED WITH ANTI-RESORPTIVE MEDICATION-RELATED OSTEONECROSIS OF THE JAWS IN OSTEOPOROTIC AND ONCOLOGICAL PATIENTS